开拓药业(09939) - 2023 - 年度业绩

Supplementary Announcement to the 2022 Annual Report and 2023 Interim Report Supplementary Information to the 2022 Annual Report Details the full utilization of 2,877.3 million HKD from Global Offering and 2021 Placing by Dec 2022, mainly for Proxalutamide and KX-826 development Use of Proceeds — Global Offering Net proceeds of 1,717.3 million HKD from the Global Offering were fully utilized by Dec 2022, mainly for Proxalutamide and KX-826 development Use of Proceeds from Global Offering | Purpose | Percentage of Net Proceeds (%) | Planned Use (million HKD) | Used in 2022 (million HKD) | Used as of December 31, 2022 (million HKD) | | :--- | :--- | :--- | :--- | :--- | | Development and Commercialization of Proxalutamide | 42.0 | 721.3 | 260.8 | 721.3 | | Development and Commercialization of KX-826 | 28.0 | 480.8 | 360.2 | 480.8 | | Clinical Trials for Other Clinical-Stage Drug Candidates | 14.0 | 240.4 | 115.5 | 240.4 | | R&D for Preclinical-Stage Drug Candidates | 6.0 | 103.1 | – | 103.1 | | Working Capital and General Corporate Purposes | 10.0 | 171.7 | – | 171.7 | | Total | 100.0 | 1,717.3 | 736.5 | 1,717.3 | Use of Proceeds — 2021 Placing of Existing Shares and Subscription of New Shares Net proceeds of 1,160.0 million HKD from the 2021 Placing were fully utilized by Dec 2022, primarily for Proxalutamide Phase III trials and commercialization preparation Use of Proceeds from 2021 Placing of Existing Shares and Subscription of New Shares | Purpose | Percentage of Net Proceeds (%) | Planned Use (million HKD) | Used in 2022 (million HKD) | Used as of December 31, 2022 (million HKD) | | :--- | :--- | :--- | :--- | :--- | | Proxalutamide International Multi-center Phase III Clinical Trials | 60.0 | 696.0 | 306.9 | 696.0 | | Procurement of Research Materials and APIs for Proxalutamide Commercialization Preparation | 33.0 | 382.8 | 69.9 | 382.8 | | Working Capital for General Corporate Purposes | 7.0 | 81.2 | – | 81.2 | | Total | 100.0 | 1,160.0 | 376.8 | 1,160.0 | Supplementary Information to the 2023 Interim Report Details the use of 782.1 million HKD net proceeds from 2022-I and 2022-II Placings as of June 2023, with 344.9 million HKD remaining for utilization by June 2024 Use of Proceeds — 2022-I Placing of Existing Shares and Subscription of New Shares Net proceeds of 273.0 million HKD from the 2022-I Placing were fully utilized by June 2023, mainly for Proxalutamide and KX-826 clinical development Use of Proceeds from 2022-I Placing of Existing Shares and Subscription of New Shares | Purpose | Percentage of Net Proceeds (%) | Planned Use (million HKD) | Used for Six Months Ended June 30, 2023 (million HKD) | Used as of June 30, 2023 (million HKD) | | :--- | :--- | :--- | :--- | :--- | | Clinical Development and Commercialization Preparation of Proxalutamide | 75.0 | 204.8 | – | 204.8 | | Clinical Development of KX-826 | 25.0 | 68.3 | 32.3 | 68.3 | | Total | 100.0 | 273.0 | 32.3 | 273.0 | Use of Proceeds — 2022-II Placing of Existing Shares and Subscription of New Shares Net proceeds of 509.1 million HKD from the 2022-II Placing, with 344.9 million HKD remaining as of June 2023, primarily for KX-826 and GT20029 clinical development Use of Proceeds from 2022-II Placing of Existing Shares and Subscription of New Shares | Purpose | Revised Allocation (%) | Amount (million HKD) | Used for Six Months Ended June 30, 2023 (million HKD) | Used as of June 30, 2023 (million HKD) | Unused as of June 30, 2023 (million HKD) | | :--- | :--- | :--- | :--- | :--- | :--- | | Clinical Development of KX-826 for Androgenetic Alopecia and Acne | 49.0 | 249.5 | 11.3 | 11.3 | 238.2 | | Clinical Development of GT20029 for Androgenetic Alopecia and Acne | 27.0 | 137.5 | 30.8 | 30.8 | 106.7 | | Clinical Development and Commercialization Preparation of Proxalutamide for COVID-19 | 15.0 | 76.4 | 76.4 | 76.4 | – | | General Working Capital | 9.0 | 45.8 | 45.8 | 45.8 | – | | Total | 100.0 | 509.1 | 164.3 | 164.3 | 344.9 | - The unused proceeds (primarily for the clinical development of KX-826 and GT20029) are expected to be fully utilized by June 2024[17][18]